News

New study links acne to higher eating-disorder risk, urging dermatologists and psychiatrists to spot warning signs and coordinate care.

Data and Safety Monitoring Board finds no safety issues for buntanetap at 6 months, keeping Annovis’ phase 3 early Alzheimer disease trial on track as enrollment progresses.

Explore how glutamate and GABA balance brain excitation and inhibition, shaping development, learning, and disorders like depression, schizophrenia, and autism.

APA shares DSM recommendations, and John J. Miller, MD, reviews and weighs in.

Learn how psychiatrists lead through change with emotional intelligence, mentorship, and early leadership roles that boost teamwork and patient safety.

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.

A new liquid stimulant option promises up to 14-hour ADHD symptom control and flexible dosing for adults and kids who struggle with capsule medication.

A psychiatrist fights denials for GLP‑1 weight-loss drugs, exposing how high costs and rigid rules deepen obesity care inequities.

Denovo teams with Orygen to test DB103, a glutamate-targeting therapy, in a phase 2 youth trial for early psychosis.

New research highlights psilocybin's potential in treating treatment-resistant OCD, while cannabinoids show little evidence of efficacy.

Explore the new Psychiatric Times digital issue, featuring articles, multimedia, and interactive learning to sharpen your clinical skills.

Learn how bupropion can trigger dose-related tinnitus and when lowering or stopping the antidepressant brings relief, with real-world clinical guidance.

New evidence reframes antidepressant withdrawal: how common, how severe, and how to taper safely without mistaking symptoms for relapse.

FDA grants priority review to Takeda’s orexin agonist oveporexton, promising phase 3 gains in wakefulness and cataplexy for narcolepsy type 1.

A rare psychiatrist-publisher dies at 97; explore Jason Aronson’s publishing legacy, Jewish studies ties, and free classic psychotherapy downloads.

Explore how AI transforms healthcare by enhancing diagnostics, personalizing treatments, and improving access while addressing significant risks and limitations.

Antidepressant withdrawal often mimics relapse; learn why hyperbolic tapering, informed consent, and slow cut-and-hold deprescribing reduce harm.

Inside the opioid epidemic: psychiatry and addiction care, MOUD options, and why stigma, policy, and jails still block lifesaving treatment.

In this Oscar-nominated film, a therapist mother spirals amid a child’s feeding disorder, exposing burnout and substance use.

This tribute to Rose Childs explores pioneering community mental health teamwork, cultural psychiatry innovation, shared leadership, and her lasting legacy in patient-centered care.

Heinrichs' POP model reaffirms the role of clinical judgment and patient-centered care.

Remembering Elise Snyder, MD, 91, who pioneered CAPA and video-based psychoanalytic training that bridged US-China mental health stigma and culture.

Review the latest in sports psychiatry before the 2026 winter Olympics.

John J. Miller, MD, weighs in on APA's plans for the DSM and why global integration with the ICD should shape psychiatry’s future.

Cognition extends zervimesine expanded access for Lewy body dementia, adding months of dosing and easier local monitoring.

Long-term antidepressant use rises in Australia, surging among individuals aged 10 to 24, with more off-label sleep and pain prescribing raising safety and withdrawal concerns.

Congress backs printing 988 on student ID cards, boosting youth crisis access and funding.

Preclinical mGlu7 negative allosteric modulator ADX71743 disrupts fear-memory reconsolidation.

Progress in psychiatry means confronting our sacred cows and shibboleths.

Explore the psychological depths of brainwashing and extremism in 2 compelling books that reveal the complexities of influence and belief.